Stomach Cancer Treatment in China: Two CLDN18.2 Doors, What a Cure Slogan Isn't
Gastric/GEJ cancer in China has two Claudin18.2 doors. Zolbetuximab is first-line with chemo (NMPA 2025). Satri-cel is CAR-T after two prior lines (22 June 2026). About 35% of screened Chinese advanced cases were CLDN18.2-positive. Send HER2 and CLDN18.2 IHC. About 24 hours. No obligation to book.
Average reply: 24 hoursNo obligation to book
CLDN stain firsttwo different doors
Zolbetuximab 1LSatri-cel later line
35% CLDN+among screened cases
Quick answer
Stomach / GEJ cancer in China has two Claudin18.2 doors that people mix up. Zolbetuximab (Vyloy) is first-line with chemo for CLDN18.2-positive, HER2-negative advanced disease (NMPA 2025). Satri-cel is CAR-T after two prior lines (NMPA 22 June 2026). About 35% of screened Chinese advanced gastric/GEJ cases were CLDN18.2-positive in Astellas’ approval materials. IARC GLOBOCAN 2024: 341,966 new cases, 248,675 deaths. Stage 4 is treated; the honest goal is often control. Send HER2 and CLDN18.2 IHC. About 24 hours. No obligation to book.
Stomach: standard GI care vs a narrow cell door
Satri-cel is not the default gastric plan. Most files stay on surgery and systemic therapy. The cell door opens only if all four boxes are true.
Claudin18.2-positive on a real report
HER2-negative
Advanced gastric or GEJ adenocarcinoma
At least two prior systemic lines
| Pathway | Usual desk | Planning figure |
|---|---|---|
| Resectable / perioperative / standard advanced | Fudan, SYSUCC, CAMS/NCC | No single band — drugs and stay |
| Satri-cel screen (label match) | PKU Cancer / designated CAR-T | Product ~RMB 990k / USD 146k + stay/CRS |
| Other solid-tumour CAR-T / TIL | Trial only | Not a walk-in product |
| Fuda as first click | Compare method with SYSUCC | Not a satri-cel substitute |
What actually changes the plan
📋
HER2 and Claudin18.2 on the file
Without those, we will not treat a satri-cel screenshot as eligibility.
🏥
GI unit vs designated CAR-T room
Fudan/SYSUCC/CAMS for standard gastric care. PKU Cancer when the label screen is real.
✈️
Stage-4 goals before flights
Control vs an actual cell-therapy screen. Two different trips, two different bills.
What this page helps you decide
✅
Satri-cel kept narrow
Four criteria, not a solid-tumour slogan. We say no when the file misses one.
💬
Standard gastric care still first
Most patients need surgery/systemic sequencing, not a cell product.
🌍
Same RMB 990k figure as CAR-T/cost
We do not invent a cheaper gastric CAR-T number for this URL.
Evidence table
IARC gastric burden, zolbetuximab GLOW/SPOTLIGHT, satri-cel Lancet PFS.
| Source | What it says | Relevance to patients |
|---|---|---|
| IARC GLOBOCAN China (2024) | 341,966 cases; 248,675 deaths | Largest gastric burden globally. |
| NMPA zolbetuximab (2025) | 1L CLDN18.2+, HER2-, with chemo; ~35% of screened Chinese patients CLDN+ | Antibody door. Not CAR-T. |
| SPOTLIGHT / GLOW China figures (2025) | PFS/OS gains as above; nausea/vomiting class effects | First-line math, not a cure rate. |
| NMPA satri-cel + Lancet (Jun 2026) | PFS 3.25 vs 1.77 after ≥2 lines; G≥3 AE 99% | Later-line CAR-T. Different door. |
Who this page is for
Advanced / stage-4 gastric or GEJ
Need honest control options and a biomarker checklist, not a cure landing page.
Patients who arrived via satri-cel news
Need the four-point label applied to their own report before anyone quotes cells.
Resectable or perioperative patients
Need a high-volume GI unit, not a cellular-therapy advertisement.
What you can actually book
PKU Cancer, CAMS/NCC, FUSCC, Ruijin (selected CAR-T rooms), SYSUCC. Related: CAR-T, cancer hub.
What moves the cost
Gastric file review
No charge to start
Stage/line read • Satri-cel label check • Centre split • Cost-driver note
Coordinated trip
Quoted after records
GI or CAR-T desk matching • Itemised drivers • Visa • Interpreter
These are routing steps, not a hospital package SKU. Published procedure examples stay in the evidence/cost sections only when a source exists. Hospital, drugs, stay, interpreter and travel are quoted separately after records.
What happens next
01
Send pathology and line history
HER2 now; Claudin18.2 if satri-cel is the question.
02
Split standard vs cell screen
Most files stay on multimodal GI oncology. A minority meet the satri-cel label.
03
Travel after the right desk accepts
GI unit or designated CAR-T centre — not a mixed Guangzhou brochure.
Request a preliminary case review
Tell us the basics of your case. When you submit, WhatsApp will open with the information you entered so you can review it before sending. This is a preliminary routing request, not a diagnosis, treatment acceptance, trial enrollment, visa decision, or medical advice.
Frequently asked questions
Is there CAR-T for stomach cancer?
Satri-cel is labelled after at least two prior lines for CLDN18.2-positive, HER2-negative advanced gastric/GEJ adenocarcinoma. It is not first-line and not CAR-T for every gastric cancer.
What is zolbetuximab?
An anti-CLDN18.2 antibody. NMPA approved it with chemo as first-line for CLDN18.2-positive, HER2-negative advanced gastric/GEJ cancer. GLOW China-subgroup PFS 8.21 vs 6.8 months.
Are zolbetuximab and satri-cel the same?
No. Antibody plus chemo first-line vs later-line CAR-T. Do not mix them in one SKU.
How many patients are CLDN18.2-positive?
Astellas' China approval materials said about 35% of screened Chinese advanced gastric/GEJ patients. Companion IHC for zolbetuximab uses a high threshold (75% of cells, moderate-to-strong membrane stain).
What did satri-cel's Lancet study show?
PFS 3.25 vs 1.77 months; grade 3 or higher adverse events in 99%; CRS common.
What records should I send?
Endoscopy pathology with HER2 and CLDN18.2 IHC, staging CT, line-by-line drug history.
Is stage 4 curable?
Stage 4 is treated. The honest goal is often control, not a cure slogan.
Do you manufacture cells?
No. Average reply about 24 hours. No obligation to book.
Do I pay before you read the file?
No. Payment required before a file review is a red flag. Average reply about 24 hours. No obligation to book.
How fast do you reply?
About 24 hours. We label the file as labelled care, trial, or marketing. No obligation to book.
Red flags in offers
CAR-T for every stomach cancer. Zolbetuximab and satri-cel mixed into one SKU. No CLDN stain on the quote.
Satri-cel quoted as first-line.
No CLDN18.2 IHC, no HER2.
CAR-T for a non-gastric solid tumour on the same PDF.
Pay before endoscopy pathology is read.
Sources
IARC GLOBOCAN 2024 China fact sheet.
NMPA English notice on zolbetuximab (Vyloy), 11 June 2025; GLOW/SPOTLIGHT China-subgroup figures; ~35% CLDN18.2-positive among screened Chinese patients.
NMPA satri-cel 22 June 2026; Lancet phase 2 PFS and toxicity.
East-Asian D2 lymphadenectomy standard (CSCO / Japanese practice).
Freshness label on this page: 2026-08-15
Medical note
A treating oncologist should review the file before travel. This page is matching information, not an infusion booking.